Free Trial

Gain Therapeutics (GANX) Competitors

Gain Therapeutics logo
$1.68 +0.08 (+5.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.69 +0.01 (+0.83%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GANX vs. ACB, NGNE, TVRD, BTMD, SLRN, TVGN, CGC, PRQR, NBTX, and YMAB

Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), biote (BTMD), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry.

Gain Therapeutics vs. Its Competitors

Aurora Cannabis (NASDAQ:ACB) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Aurora Cannabis has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gain Therapeutics has a consensus target price of $8.20, indicating a potential upside of 388.10%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.67
Gain Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Aurora Cannabis has a net margin of 1.32% compared to Gain Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis1.32% 0.13% 0.10%
Gain Therapeutics N/A -247.55%-146.06%

In the previous week, Aurora Cannabis and Aurora Cannabis both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 0.53 beat Aurora Cannabis' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gain Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aurora Cannabis has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$246.72M1.04$1.63M$0.1141.45
Gain Therapeutics$50K1,006.32-$20.41M-$0.86-1.95

Summary

Aurora Cannabis beats Gain Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GANX vs. The Competition

MetricGain TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$50.32M$2.37B$5.46B$8.92B
Dividend YieldN/A1.78%5.24%4.04%
P/E Ratio-1.958.9127.0120.12
Price / Sales1,006.32499.49380.1493.35
Price / CashN/A21.7726.2128.59
Price / Book6.004.537.995.57
Net Income-$20.41M$31.26M$3.16B$248.40M
7 Day Performance7.01%5.57%3.69%6.04%
1 Month Performance-12.50%5.48%2.91%7.69%
1 Year Performance50.00%1.14%34.30%20.97%

Gain Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GANX
Gain Therapeutics
3.0439 of 5 stars
$1.68
+5.0%
$8.20
+388.1%
+33.3%$50.32M$50K-1.9520Positive News
ACB
Aurora Cannabis
0.099 of 5 stars
$4.24
+2.2%
N/A-8.1%$233.29M$246.72M38.551,130
NGNE
Neurogene
3.7905 of 5 stars
$14.95
-7.5%
$46.17
+208.8%
-42.9%$230.48M$930K-3.4490
TVRD
Tvardi Therapeutics
N/A$23.33
-5.2%
$71.50
+206.5%
N/A$230.37M$7.14M0.0080
BTMD
biote
3.0952 of 5 stars
$4.02
-4.3%
$8.00
+99.0%
-46.0%$229.78M$197.19M6.59194News Coverage
Positive News
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
TVGN
Semper Paratus Acquisition
3.9649 of 5 stars
$1.25
+0.8%
$10.00
+700.0%
+71.4%$228.03MN/A0.003
CGC
Canopy Growth
2.8393 of 5 stars
$1.22
flat
$2.00
+63.9%
-81.1%$224.32M$225.65M-0.303,150
PRQR
ProQR Therapeutics
2.1135 of 5 stars
$2.04
flat
$8.00
+292.2%
+25.9%$214.63M$20.46M-5.83180News Coverage
NBTX
Nanobiotix
1.6904 of 5 stars
$4.73
+4.4%
$8.00
+69.1%
-13.1%$213.34M$39.18M0.00100News Coverage
Positive News
Gap Up
YMAB
Y-mAbs Therapeutics
3.15 of 5 stars
$4.51
-4.0%
$15.60
+245.9%
-63.0%$212.84M$88.66M-7.05150

Related Companies and Tools


This page (NASDAQ:GANX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners